Liquid biopsy and minimal residual disease — latest advances and implications for cure

Liquid biopsy and minimal residual disease — latest advances and implications for cureLiquid biopsy and minimal residual disease — latest advances and implications for cure, Published online: 22 February 2019; doi:10.1038/s41571-019-0187-3In this Review, Pantel and Alix-Panabières provide an overview of approaches for the detection and characterization of minimal residual disease (MRD) using circulating tumour cells and circulating tumour DNA. They also discuss the clinical implications of such liquid biopsy approaches to MRD monitoring for the management of patients with cancer.

Source: Nature Clinical Practice Oncology - February 22, 2019 Category: Cancer & Oncology Authors: Klaus Pantel Catherine Alix-Panabi ères Source Type: research